Top ▲

Pyoderma gangrenosum

Disease ID:1240
Name:Pyoderma gangrenosum
Associated with:0 target
1 immuno-relevant ligand
A sterile inflammatory ulcerative condition of the skin, likely due to an overactive immune reaction to skin trauma, or another disease, characterised by neutrophil infiltration and mucopurulent or hemorrhagic exudate. A significant proportion of cases are comorbid with autoimmune conditions.
Database Links
Disease Ontology: DOID:8553
Orphanet: ORPHA48104


No target related data available for Pyoderma gangrenosum


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Phase 2 clinical candidate for this condition (see NCT03072953).
Clinical Use: Etrasimod (APD334) was advanced to clinical trial in patients with moderately to severely active ulcerative colitis (see NCT02536404). It was approved for this indication by the FDA in October 2023. | View clinical data
Bioactivity Comments: In in vitro β-arrestin recruitment assays APD334 has no measurable activity at S1P2 and S1P3 receptors, and low activity at S1P4 receptors [1]. EC50 for S1P5 receptors is around 4-fold lower than for the primary target S1P1. APD334 has similar ability to induce cAMP accumulation across S1P1 receptors from species including human, rat, mouse, monkey and dog. APD334 produces robust lymphocyte lowering in several preclinical species, and is effective in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis [1]. | View biological activity


Show »

1. Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J, Thoresen L, Calderon I, Ullman B, Han S et al.. (2014) Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor. ACS Med Chem Lett, 5 (12): 1313-7. [PMID:25516790]